vs
Side-by-side financial comparison of Arbutus Biopharma Corp (ABUS) and Broadway Financial Corp (BYFC). Click either name above to swap in a different company.
Arbutus Biopharma Corp is the larger business by last-quarter revenue ($10.7M vs $9.4M, roughly 1.1× Broadway Financial Corp). Broadway Financial Corp runs the higher net margin — 1934.0% vs 23.5%, a 1910.5% gap on every dollar of revenue. On growth, Arbutus Biopharma Corp posted the faster year-over-year revenue change (522.2% vs 10.1%). Over the past eight quarters, Broadway Financial Corp's revenue compounded faster (9.7% CAGR vs -13.2%).
Arbutus Biopharma Corporation is a publicly traded Canadian biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection.
Virtu Financial, Inc. is an American high-frequency trading company. The company went public on the Nasdaq in 2015.
ABUS vs BYFC — Head-to-Head
Income Statement — Q2 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $10.7M | $9.4M |
| Net Profit | $2.5M | $1.0M |
| Gross Margin | — | — |
| Operating Margin | 13.9% | — |
| Net Margin | 23.5% | 1934.0% |
| Revenue YoY | 522.2% | 10.1% |
| Net Profit YoY | 112.7% | -21.8% |
| EPS (diluted) | $0.01 | $0.02 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $9.4M | ||
| Q3 25 | — | $9.0M | ||
| Q2 25 | $10.7M | $8.1M | ||
| Q1 25 | — | $8.3M | ||
| Q4 24 | — | $8.6M | ||
| Q3 24 | — | $8.7M | ||
| Q2 24 | — | $8.2M | ||
| Q1 24 | — | $7.8M |
| Q4 25 | — | $1.0M | ||
| Q3 25 | — | $-23.9M | ||
| Q2 25 | $2.5M | $752.0K | ||
| Q1 25 | — | $-2.7M | ||
| Q4 24 | — | $1.3M | ||
| Q3 24 | — | $516.0K | ||
| Q2 24 | — | $256.0K | ||
| Q1 24 | — | $-154.0K |
| Q4 25 | — | — | ||
| Q3 25 | — | -256.2% | ||
| Q2 25 | 13.9% | 12.8% | ||
| Q1 25 | — | -45.3% | ||
| Q4 24 | — | 21.7% | ||
| Q3 24 | — | 8.5% | ||
| Q2 24 | — | 4.8% | ||
| Q1 24 | — | -2.9% |
| Q4 25 | — | 1934.0% | ||
| Q3 25 | — | -264.2% | ||
| Q2 25 | 23.5% | 9.3% | ||
| Q1 25 | — | -32.3% | ||
| Q4 24 | — | 15.3% | ||
| Q3 24 | — | 5.9% | ||
| Q2 24 | — | 3.1% | ||
| Q1 24 | — | -2.0% |
| Q4 25 | — | $0.02 | ||
| Q3 25 | — | $-2.86 | ||
| Q2 25 | $0.01 | $0.00 | ||
| Q1 25 | — | $-0.39 | ||
| Q4 24 | — | $0.07 | ||
| Q3 24 | — | $-0.03 | ||
| Q2 24 | — | $0.02 | ||
| Q1 24 | — | $-0.02 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $37.4M | $10.5M |
| Total DebtLower is stronger | $0 | — |
| Stockholders' EquityBook value | $83.0M | $262.8M |
| Total Assets | $103.3M | $1.3B |
| Debt / EquityLower = less leverage | 0.00× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $10.5M | ||
| Q3 25 | — | $19.7M | ||
| Q2 25 | $37.4M | $29.5M | ||
| Q1 25 | — | $15.8M | ||
| Q4 24 | — | $61.4M | ||
| Q3 24 | — | $97.1M | ||
| Q2 24 | — | $89.8M | ||
| Q1 24 | — | $67.1M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $0 | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | $262.8M | ||
| Q3 25 | — | $261.7M | ||
| Q2 25 | $83.0M | $284.7M | ||
| Q1 25 | — | $283.6M | ||
| Q4 24 | — | $285.0M | ||
| Q3 24 | — | $286.2M | ||
| Q2 24 | — | $282.1M | ||
| Q1 24 | — | $281.1M |
| Q4 25 | — | $1.3B | ||
| Q3 25 | — | $1.3B | ||
| Q2 25 | $103.3M | $1.2B | ||
| Q1 25 | — | $1.3B | ||
| Q4 24 | — | $1.3B | ||
| Q3 24 | — | $1.4B | ||
| Q2 24 | — | $1.4B | ||
| Q1 24 | — | $1.4B |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.00× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.7M | $230.0K |
| Free Cash FlowOCF − Capex | — | $-13.0K |
| FCF MarginFCF / Revenue | — | -0.1% |
| Capex IntensityCapex / Revenue | 0.0% | 2.6% |
| Cash ConversionOCF / Net Profit | -6.24× | 0.22× |
| TTM Free Cash FlowTrailing 4 quarters | — | $2.3M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $230.0K | ||
| Q3 25 | — | $3.8M | ||
| Q2 25 | $-15.7M | $3.0M | ||
| Q1 25 | — | $-4.3M | ||
| Q4 24 | — | $1.4M | ||
| Q3 24 | — | $6.1M | ||
| Q2 24 | — | $9.8M | ||
| Q1 24 | — | $-11.7M |
| Q4 25 | — | $-13.0K | ||
| Q3 25 | — | $3.7M | ||
| Q2 25 | — | $3.0M | ||
| Q1 25 | — | $-4.4M | ||
| Q4 24 | — | $1.3M | ||
| Q3 24 | — | $6.1M | ||
| Q2 24 | — | $9.7M | ||
| Q1 24 | — | $-11.7M |
| Q4 25 | — | -0.1% | ||
| Q3 25 | — | 41.1% | ||
| Q2 25 | — | 37.0% | ||
| Q1 25 | — | -52.4% | ||
| Q4 24 | — | 14.7% | ||
| Q3 24 | — | 69.6% | ||
| Q2 24 | — | 118.9% | ||
| Q1 24 | — | -149.7% |
| Q4 25 | — | 2.6% | ||
| Q3 25 | — | 1.2% | ||
| Q2 25 | 0.0% | 0.2% | ||
| Q1 25 | — | 0.2% | ||
| Q4 24 | — | 1.6% | ||
| Q3 24 | — | 0.3% | ||
| Q2 24 | — | 0.5% | ||
| Q1 24 | — | 0.7% |
| Q4 25 | — | 0.22× | ||
| Q3 25 | — | — | ||
| Q2 25 | -6.24× | 4.00× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 1.06× | ||
| Q3 24 | — | 11.85× | ||
| Q2 24 | — | 38.21× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
